The Union Budget on Sunday proposed a tax holiday till 2047 for foreign companies that provide cloud services to customers globally using data centres located in India, signalling the government's push to make the country a major hub for AI and digital infrastructure.
The Union Budget on Sunday proposed a tax holiday till 2047 for foreign companies that provide cloud services to customers globally using data centres located in India, signalling the government's push to make the country a major hub for AI and digital infrastructure.
Two Delhi-based traders were arrested in Hapur after attempting to cremate a mannequin instead of a human body to fraudulently claim insurance money. The scheme involved using the identity of an employee's brother to obtain a life insurance policy and then staging his death.
'They are positioned as defensive products and can potentially give marginally higher returns than liquid funds.'
The Eastern Freeway, Sion-Panvel highway, V N Purav Road, P D'Mello Road, Wallchand Hirachand Marg, Dr Dadabhai Nauroji Road and Hajarimal Somani Road will be closed for all types of vehicular traffic except emergency service vehicles, said the official.
One of Debashish Bhattacharya's most remarkable contributions is that he has taken the scope and foundation of the slide guitar, improvised it again and again, thereby designing and creating four entirely new guitars.
In the doubles draw, Indian pair Siddhant Banthia and Parikshit Somani beat compatriots Sai Karteek Reddy Ganta and Vishnu Vardhan 6-3, 3-6, 10-7 to book their spot in the quarter-finals.
'Safety is my first priority.' 'I need to ensure that any drug or vaccine that our citizens get is first safe.'
Stocks of the country's bigger tile and ceramic makers were major gainers over the past week. The leaders in this space -- Kajaria Ceramics and Cera Sanitaryware -- were up 7 per cent each. In the past three months, Kajaria Ceramics and Somany Ceramics were up 29-32 per cent, while Cera Sanitaryware gained 22 per cent.
India will begin its campaign on October 8 against Australia in Chennai.
Hotel room tariff in Ahmedabad, airfares shoot up ahead of India-Australia final
In the letter, Somani said the samples of four made-in-India cough syrups linked to the deaths of 66 children in Gambia which were tested in government laboratory here were found to be complying with specifications and not to have been contaminated with DEG or EG according to the test reports.
Kajaria Ceramics, the country's leading listed tile manufacturer, has seen its stock fall by 7 per cent over the past month amid concerns about rising input costs and sluggish domestic demand. Other listed stocks also experienced weakness in September, although there was some recovery in October. While strong exports are expected to help stabilise domestic market prices, the surge in gas prices over the past couple of months may have impacted margins in the second half of FY24.
The DCGI said it has no objection in respect of 'Extension of Shelf Life of Covishield Vaccine' in multi-dose glass vial (10 dose-5ml) from six months to nine months.
Samples of the cough syrup have been taken from the manufacturing premises in Noida and sent to the Regional Drugs Testing Laboratory (RDTL) in Chandigarh for testing, Mandaviya said.
Notwithstanding the risk involved, analysts are upbeat on micro-cap investing as India remains in a firm bull market. Moreover, these stocks are available at relatively cheaper valuations compared to large, mid and small caps, assuring alpha returns. With a market-capitalisation (market-cap) of up to Rs 10,000 crore, micro-cap stocks are outside the purview of Nifty 500 stocks, and are ranked from 501 to 750 in the market-cap ladder.
With regulatory uncertainties clouding the future of online pharmacies, deals in the space are showing signs of slowdown, as also fresh investment from private-equity (PE) firms and venture capitalists (VCs). The data from Venture Intelligence shows so far in 2023 (as of June 13) there has been one deal with PE-VC funding. In 2022 there were four, a sharp fall from the 12, totalling $1,520 million, the sector had attracted in 2021.
The show-cause notice dated February 8 by DCGI V G Somani cited a Delhi high court order dated December 12, 2018, which prohibits online sales of medicines without a licence.
The approval by the Drugs Controller General of India (DCGI) was given on the basis of recommendations submitted by a COVID-19 subject expert committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).
The Serum Institute of India, Bharat Biotech and Pfizer have applied to the DCGI seeking emergency use authorisation for their COVID-19 vaccine candidates and are awaiting approval.
The DCGI also directed Serum Institute of India to increase the safety monitoring of the subjects already vaccinated as part of the trial, and submit the plan and report.
The joint inspections is to ensure the safety, efficacy, and quality of drugs available in the country
The central government is importing COVID-19 vaccines and is in talks with COVID-19 vaccine manufacturers Pfizer and Johnson & Johnson, Union Minister of State for Home Affairs G Kishan Reddy said.
'Your family, your kith and kin are also under stress, some of your relatives will die, without getting appropriate treatment.'
Written informed consent of each patient is required before the use of this drug, he said
"We will never approve anything if there is even the slightest safety concern. Vaccines are 110 per cent safe. Some side effects like mild fever, pain and allergy are common for every vaccine. "It (rumours of impotency) is complete nonsense," V G Somani, Drug Controller General of India said.
'The only way to contain this is to see that a lesser number of people are affected.'
SII has been asked to submit to the DCGI's office details of medication used in accordance with the protocol for management of adverse events.
There were apprehensions in the SII about rival Bharat Biotech's 'indigenous' tag, opening up shortcuts for it. One senior person, who was very familiar with the sector, told me, 'The message has gone out from the very top. Somani (V G Somani -- drug controller general of India) has told me "Bharat ka karna hai".' A fascinating excerpt from Abantika Ghosh's Billions Under Lockdown: The Inside Story Of India's Fight Against COVID-19.
The global trials were halted after a study participant suffered a 'potentially unexplained illness, reports Sohini Das.
The show-cause notice was issued following reports that human trials of the most promising COVID-19 vaccine candidate, being developed by the University of Oxford, have been put on hold after a United Kingdom participant had an adverse reaction to it.
Of the 23.9 million vaccinators who provide vaccination under the universal immunisation programme, 15.4 million will be used for Covid vaccination.
Paul noted that "three to four months from now, there will be other vaccines and the stockpile will be even bigger. "And more acceleration can be brought about in the vaccination programme," Paul added.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
The move comes even as India's drug regulator has extended Covishield's shelf life from six to nine months from its manufacturing date.
'...of the non-availability of doctor expertise or appropriate treatment.' 'That's because of the nature of the disease at this point of time, it is very difficult to contain.'
The Drug Controller General of India has sent a letter to the Glenmark seeking clarifications on pricing as well as claims of therapeutic efficacy. While Glenmark has claimed this drug is effective in comorbid conditions like diabetes, hypertension, according to protocol summary (of clinical trials) the trial was not designed to access the Fabiflu in comorbid conditions.
Earlier this week, AstraZeneca said it had paused the trials because of 'an unexplained illness' in a participant in the study.
E-commerce is driving thoughts of customers.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances